Members of the House Energy and Commerce Committee blasted the Food and Drug Administration (FDA) last week for urging drug companies to withhold information on the efficacy of antidepressants used on children. The controversy comes just as patient advocacy groups, the American Medical Association, and a dozen medical journal editors are calling on pharmaceutical companies to register their clinical trials in order to meet increasing public demand for information on the effectiveness and safety of drugs. Lack of Information on Clinical Trials Leads to Use of Ineffective Drugs

OMB Watch's new report, The Bush Regulatory Record: A Pattern of Failure, analyzes the last year of federal regulatory activity for four key agencies charged with serving the public interest and places its findings in a broader four-year context. The agencies studied are the Environmental Protection Agency (EPA), the Food and Drug Administration (FDA), the National Highway Traffic Safety Administration (NHTSA), and the Occupational Safety and Health Administration (OSHA).

42 U.S.C. § 282 Sec. 282. - Director of National Institutes of Health (j) Data bank of information on clinical trials for drugs for serious or life-threatening diseases and conditions

The National Marine Fisheries Service (NMFS) announced August 31 it will not consider removing dams in the Columbia and Snake rivers in order to save the endangered salmon population. The announcement contradicts twenty years of research by both environmental groups and government agencies that supports breaching the dams as the most effective way to save the endangered fish population.